BOTHELL, Wash., April 30, 2026
Cocrystal Pharma, Inc., a clinical-stage biotechnology company focused on antiviral therapeutics, has presented new data highlighting the mechanism of action and clinical advancement of its lead candidate CDI-988 at the International Conference on Antiviral Research (ICAR 2026). The update underscores the potential of CDI-988 as a first-in-class oral direct-acting antiviral for the prevention and treatment of norovirus infection, a condition with no currently approved therapies or vaccines.The presentation detailed progress from ongoing clinical studies, including a Phase 1b human challenge trial, designed to establish proof-of-concept for both prophylactic and therapeutic use. This advancement positions CDI-988 as a promising candidate in addressing a significant global health burden caused by norovirus infections.
Clinical Development Progress and Trial Milestones
Cocrystal Pharma reported that the first cohort of the Phase 1b human challenge study has been fully enrolled, marking a key milestone in the clinical evaluation of CDI-988. The study is designed to assess the infectivity of the norovirus inoculum and evaluate the drug’s ability to reduce clinical symptoms and viral shedding in healthy adult participants
The trial follows a successful randomized, double-blind, placebo-controlled Phase 1 study, where CDI-988 demonstrated a favorable safety and tolerability profile across multiple dose levels, with no serious adverse events reported. These findings support continued clinical development and highlight the therapy’s potential for broad clinical application in both prevention and treatment settings.
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CDI-988, recognizing the urgent need for effective therapies against norovirus and enabling accelerated development and regulatory review pathways. This designation further validates the importance of the program in addressing unmet medical needs.
Advertisement
Innovative Mechanism Targets Norovirus Replication
CDI-988 is a novel oral protease inhibitor developed using structure-based drug discovery technology, targeting the highly conserved 3CL protease enzyme essential for norovirus replication. By focusing on this conserved region, the therapy is designed to be effective across multiple norovirus genotypes and variants, overcoming challenges associated with viral diversity.
Preclinical studies have demonstrated potent antiviral activity in human enteronoid models, along with favorable gastrointestinal-targeted pharmacokinetics, ensuring that the drug reaches the primary site of infection. This targeted approach enhances its therapeutic potential and differentiates it from traditional antiviral strategies.
The ability of CDI-988 to provide both preventive and therapeutic benefits in a convenient oral formulation represents a significant advancement, particularly in outbreak-prone environments such as hospitals, schools, and cruise ships. Its design also allows for stockpiling and rapid deployment during outbreaks, addressing a critical gap in public health preparedness.
Addressing a Major Global Health Burden
Norovirus is the leading cause of acute gastroenteritis worldwide, responsible for approximately 685 million cases and 200,000 deaths annually, with an estimated $60 billion global economic impact. The virus is highly contagious and frequently causes outbreaks in semi-closed environments, posing a significant challenge for healthcare systems and public health authorities.
Despite extensive research efforts, no approved vaccines or antiviral treatments currently exist, largely due to the virus’s genetic diversity and rapid mutation rates. CDI-988’s ability to target conserved viral mechanisms positions it as a potential breakthrough solution in this space.
Cocrystal Pharma’s advancement of CDI-988 reflects a broader shift toward precision antiviral therapies, leveraging molecular insights to develop more effective and durable treatments. As the Phase 1b study progresses and additional data emerge, the therapy could play a pivotal role in reducing the clinical and economic burden of norovirus infections globally.
With strong early data, regulatory support, and a clear development pathway, CDI-988 stands out as a promising candidate that could redefine the prevention and treatment of norovirus, addressing one of the most widespread infectious diseases worldwide.
From a GxP perspective, the transition into clinical trials emphasizes the importance of data integrity, patient safety, and robust trial design, all of which are essential for advancing therapies through regulatory pathways. As Laguna progresses its clinical program, LGNA-100 could play a transformative role in reducing relapse rates and improving survival outcomes for patients with high-risk leukemia, reinforcing the company’s mission to deliver next-generation, system-level therapies for complex diseases.
Source: Cocrystal Pharma press release
